![](https://siapsprogram.org/wp-content/uploads/2019/11/17-199_Thumb_Page_1-100x142.png)
Inside this issue: Pharmacovigilance in Swaziland Update on 2016-2017 Spontaneous Reporting Systems Medicine Safety Alerts How to Report an ADE
Inside this issue: Pharmacovigilance in Swaziland Update on 2016-2017 Spontaneous Reporting Systems Medicine Safety Alerts How to Report an ADE
With support from SIAPS, the Swaziland National Pharmacovigilance Unit (NPVU) has been monitoring the safety of medicines used in the county by collecting and collating reports of adverse drug reactions (ADR) and other medicine-related problems through its spontaneous reporting system established under the country’s Ministry of Health in 2009. In addition, SIAPS has been supporting … Read more
As a pharmacist, Md. Jahidul Hasan has worked in several hospitals, but it was not until he joined Square Hospital Limited (SHL) that he learned about pharmacovigilance (PV). SHL is a 400-bed tertiary care private hospital in Dhaka, Bangladesh, that serves an average of 1,200 out-patients each day. The Directorate General of Drug Administration (DGDA), with … Read more
SIAPS supported the Swaziland Ministry of Health (MOH) in mobilizing key stakeholders from the Swaziland National AIDS Program and the National Tuberculosis Control Program to introduce and implement an active surveillance system for patients on ARVs and anti-TB treatment. SIAPS provided technical assistance to MOH’s National Pharmacovigilance Unit (NPVU) to develop the protocol and tools to implement … Read more
A pharmacovigilance system, through active surveillance in sentinel sites, is proposed to monitor the safety and tolerability of antiretroviral medicines (ARV) and anti-tuberculosis (TB) medicines at antiretroviral treatment (ART) clinics and TB clinics in Swaziland. The goal of this activity is to develop, implement, and demonstrate the local feasibility of a practical and sustainable pharmacovigilance … Read more
The goal of SIAPS in Namibia was to improve the quality and safety of pharmaceutical services to achieve sustained HIV epidemic control. Since 2012, SIAPS focused on interventions that increased the availability of quality antiretrovirals (ARVs), other essential medicines, and services to sustain more than 80% ART coverage of patients in need. SIAPS activities also … Read more
TB patients on second-line treatment experience a significant number of adverse effects. Some TB medicines result in adverse effects that, if not continuously monitored, can become serious and/or permanent and may hinder patient adherence to treatment. A number of other risk factors can also impact the safety of patients taking TB medicines, including drug interactions … Read more
SIAPS, in partnership with the FDA, NTP, and LCP-NCPR, conducted a readiness assessment to determine the current information technology (IT) infrastructure, human resources, processes, and data management and quality control mechanisms available and to identify gaps in the current PV recording and reporting of patients in the seven Programmatic Management of Drug-Resistant TB (PMDT) treatment … Read more
An online system for monitoring and reporting cases of adverse drug reactions and lack of efficacy of medicines comprehensively addresses the need for improved access to quality, safe, and effective medicines. “The evaluation and analysis of PAIS system in Ukraine has brought out gaps and identified recommendations on operational PAIS system optimization and enhancing its … Read more
The SIAPS team has helped the Ethiopian Food, Medicine, and Health Care Administration and Control Authority (FMHACA) and many health facilities in the country incorporate product quality reporting into its national adverse drug event (ADE) reporting system. This has proven to be an efficient and cost-effective measure to detect products with problems in quality and … Read more